Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Kent

MOHS-Micrographic Surgery Macon, GA Medical Doctor

NPI 1881127587 CMS profile 3672974

308 Coliseum Dr Ste 200, Macon, GA 31217

Open in the dashboard

General payments

$8,079

321 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$22,032 paid to institutions, not to them · program year 2025

Through program year 2025, Steven Kent of Macon, GA is reported in the CMS Open Payments database as having received $8,079 across 321 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $22,032 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,446 110
2024 General $1,477 70
2023 General $1,975 77
2022 General $496 21
2021 General $123 7
2020 General $226 8
2019 General $1,336 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Kent
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Steven Kent were reported at $2,446. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Steven Kent MOHS-Micrographic Surgery median Middle half National median
2019 $1,336 $316 $106–$785 $163
2020 $226 $162 $68–$412 $114
2021 $123 $243 $87–$654 $132
2022 $496 $300 $102–$887 $149
2023 $1,975 $364 $125–$1,010 $160
2024 $1,477 $445 $142–$1,108 $164
2025 $2,446 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,518 117 payments
  2. Genzyme Corporation $782 28 payments
  3. Regeneron Healthcare Solutions, Inc. $617 25 payments
  4. Dermavant Sciences, Inc. $424 20 payments
  5. Novartis Pharmaceuticals Corporation $410 14 payments
  6. Janssen Biotech, Inc. $382 12 payments
  7. Celgene Corporation $375 3 payments
  8. Organogenesis Inc. $354 11 payments
  9. Incyte Corporation $294 14 payments
  10. Pfizer Inc. $288 13 payments
  11. Other $1,635 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,786 316 payments
  2. Education $293 5 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI Immunology $999 53 payments
  2. DUPIXENT $941 35 payments
  3. RINVOQ $871 41 payments
  4. VTAMA $428 21 payments
  5. TREMFYA $378 12 payments
  6. Otezla $375 3 payments
  7. SKYRIZI Immunology $371 21 payments
  8. LIBTAYO $301 12 payments
  9. OPZELURA $294 14 payments
  10. COSENTYX $237 10 payments
  11. Other $3,920 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

544

Median for Dermatology: 534

Drug cost

$85,196

Median for Dermatology: $67,151

Branded share of claims

8.3%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 12 $75,936
Tacrolimus Generic 15 $1,728
Clobetasol Propionate Generic 39 $1,610
Fluorouracil Generic 26 $1,505
Ketoconazole Generic 44 $748
Doxycycline Hyclate Generic 106 $706
Triamcinolone Acetonide Generic 45 $575
Valacyclovir Valacyclovir Hcl Brand 22 $427
Cefdinir Generic 29 $371
Ciclopirox Ciclopirox Olamine Brand 11 $345

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$527,781

Of which drugs: $209,929

Medicare patients

682

Average age 76

Services billed

2,844

319 women, 363 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Chronic kidney disease 30%
Diabetes 29%
Ischemic heart disease 28%
Atrial fibrillation 21%
Cancer 16%
Depression 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $420
$420 — —
RINVOQ
  • AbbVie, Inc. $308
$308 12 —
DUPIXENT
  • GENZYME CORPORATION $125
$125 — —
OPZELURA
  • Incyte Corporation $122
$122 — —
VTAMA
  • Dermavant Sciences, Inc. $116
$116 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

321 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record